PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 158 filers reported holding PUMA BIOTECHNOLOGY INC in Q3 2018. The put-call ratio across all filers is 0.93 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $600,000 | -8.4% | 85,600 | +20.1% | 0.01% | 0.0% |
| Q2 2021 | $655,000 | -7.2% | 71,300 | -1.8% | 0.01% | -14.3% |
| Q1 2021 | $706,000 | +19.5% | 72,600 | +26.0% | 0.01% | +16.7% |
| Q4 2020 | $591,000 | +7.7% | 57,600 | +5.9% | 0.01% | 0.0% |
| Q3 2020 | $549,000 | -5.8% | 54,400 | -2.7% | 0.01% | -14.3% |
| Q2 2020 | $583,000 | +540.7% | 55,900 | +417.6% | 0.01% | +600.0% |
| Q1 2020 | $91,000 | -91.2% | 10,800 | -52.2% | 0.00% | -91.7% |
| Q3 2018 | $1,036,000 | -22.5% | 22,600 | 0.0% | 0.01% | -25.0% |
| Q2 2018 | $1,337,000 | -6.9% | 22,600 | +7.1% | 0.02% | -5.9% |
| Q1 2018 | $1,436,000 | +3.0% | 21,100 | +49.6% | 0.02% | +6.2% |
| Q4 2017 | $1,394,000 | -4.6% | 14,100 | +15.6% | 0.02% | -11.1% |
| Q3 2017 | $1,461,000 | +203.7% | 12,200 | +121.8% | 0.02% | +200.0% |
| Q2 2017 | $481,000 | +29.6% | 5,500 | -54.5% | 0.01% | +20.0% |
| Q4 2016 | $371,000 | -54.3% | 12,100 | 0.0% | 0.01% | -58.3% |
| Q3 2016 | $811,000 | – | 12,100 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Cormorant Asset Management, LP | 200,000 | $20,706,000 | 6.01% |
| Redmile Group, LLC | 230,673 | $23,882,000 | 2.95% |
| WEATHERBIE CAPITAL, LLC | 241,419 | $24,994,000 | 2.31% |
| Tekla Capital Management LLC | 185,820 | $19,238,000 | 2.02% |
| Ghost Tree Capital, LLC | 25,000 | $2,588,000 | 1.59% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,686,668 | $588,741,000 | 1.56% |
| Iguana Healthcare Management, LLC | 25,000 | $2,588,000 | 1.48% |
| Eventide Asset Management | 42,100 | $4,359,000 | 1.34% |
| Bain Capital Public Equity Management, LLC | 401,330 | $41,550,000 | 1.17% |
| Rock Springs Capital Management LP | 31,500 | $3,261,000 | 1.16% |